The latest issue of Advances in Pulmonary Hypertension focuses on a variety of compelling topics. Advances is the Pulmonary Hypertension Association’s quarterly peer-reviewed clinical journal.

The latest issue includes:

• Roundtable Discussion: Drug and Toxin
• Pharmacovigilance of Rare Drug-Induced Disease: A Focus on Pulmonary Arterial Hypertension
• Methamphetamine-Associated Pulmonary Arterial Hypertension 
• Pulmonary Arterial Hypertension Treatment Algorithm

“The message of this issue is clear: Drug- and toxin-associated PAH is not a niche category but a window into disease causation, a test of our clinical vigilance, and an opportunity for prevention,” say guest editors Roham Zamanian, MD, and Vinicio de Jesus Perez, MD. “The opportunity is in front of us; the question is whether we are prepared to act on it.”